.jpg)
Pfenex is utilizing Pfēnex Expression TechnologyTM to build a comprehensive portfolio of biosimilar molecules. No advantages are gained by simply repeating an innovator’s protein expression and bioprocess strategy that may have been developed more than 20 years ago. Pfenex applies its parallel processing, toolbox approach to strain development to arrive at a highly advantaged expression strain and bioprocess. Capitalizing on the cost effectiveness of the Pfenex protein expression Technology-based processes and the proven ability to rapidly identify a robust production strain, Pfenex is becoming a global leader in biosimilar development.
Pfenex currently has three biosimilar molecules in development. We are currently seeking co-development partners on these, and on other new biosimilar programs.